07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Natera, Sequenom, Thermo Fisher, Roche diagnostic news

The U.S. Supreme Court declined to review a lower court decision invalidating U.S. Patent No. 6,258,540 covering prenatal diagnosis with nucleic acid analysis used in Sequenom’s MaterniT21 Plus laboratory-developed test. Sequenom had asked SCOTUS to...
00:29 , Jul 7, 2016 |  BC Extra  |  Politics & Policy

CAFC vacates decision that invalidated a process patent

The U.S. Court of Appeals for the Federal Circuit found that a patent covering a process for preserving hepatocytes by multiple freeze-thaw cycles was not directed to a patent-ineligible law of nature, vacating a lower...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Company News

Artisan Pharma, Asahi Kasei Pharma deal

Asahi acquired its 2006 spinout Artisan. Asahi said Artisan will become its base for U.S. development of pharmaceuticals. Artisan has rights to Asahi's ART-123 outside of Japan, China, Taiwan and South Korea. The soluble form...
07:00 , May 3, 2010 |  BC Week In Review  |  Clinical News

ART-123: Completed Phase IIb enrollment

Artisan completed enrollment of 750 sepsis patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating 6 mg/mL injectable ART-123. The product is approved for the indication in Japan. Artisan spun out of Asahi in...
08:00 , Feb 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Transplantation Renal transplant High mobility group box-1 (HMGB-1); toll-like receptor 4 (TLR4) Studies in humans and in cell culture suggest...
08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Caspase-7 Studies in mice suggest that caspase-7 downregulation could help treat septic shock and endotoxemia. In a...
07:00 , Sep 29, 2008 |  BioCentury  |  Emerging Company Profile

Artisan: Testing, testing 123

Many companies have failed to develop therapeutics for sepsis, and the only drug approved for the indication has met with little clinical or commercial success. Artisan Pharma Inc. believes its ART-123 will succeed where others...
07:00 , Sep 29, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Artisan Pharma Inc. Waltham, Mass. Technology: Recombinant human thrombomodulin ( ART-123 ) Disease focus: Cardiovascular Clinical status: Phase IIb Founded: 2006 as a spinout of Asahi Kasei Pharma Corp. University collaborators: Undisclosed Corporate partners: Asahi...
07:00 , Apr 7, 2008 |  BioCentury  |  Finance

1Q approvals/1Q setbacks

1Q approvals/1Q setbacks 1Q approvals Selected first quarter product approvals. Company Approval Abbott (NYSE:ABT) FDA approves Simcor, a fixed-dose combination of extended-release niacin and immediate-release simvastatin, to manage cholesterol in patients with complex lipid disease...
08:00 , Feb 25, 2008 |  BC Week In Review  |  Clinical News

ART-123 regulatory update

Last month, the Japanese Pharmaceutical and Medical Device Agency (J-PMDA) approved an NDA from Asahi Kasei for ART-123 to treat disseminated intravascular coagulation (DIC) in sepsis. Artisan, which spun out of Asahi Kasei in 2006,...